Country: Canada
Language: English
Source: Health Canada
DOCETAXEL
TARO PHARMACEUTICALS INC
L01CD02
DOCETAXEL
160MG
SOLUTION
DOCETAXEL 160MG
INTRAVENOUS
100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0127884004; AHFS:
CANCELLED PRE MARKET
2022-07-11
_ _ _Pr_ _Taro-Docetaxel - Product Monograph _ _ _ _Page 1 of 57 _ PRODUCT MONOGRAPH PR TARO-DOCETAXEL (Docetaxel for Injection) Single Vial Formulation CONCENTRATED SOLUTION 20 MG / ML 80 MG / 4 ML 160 MG / 8 ML USP Standard FOR INTRAVENOUS INFUSION, MUST BE DILUTED BEFORE USE ANTINEOPLASTIC AGENT Taro Pharmaceuticals Inc. Date of Revision: 130 East Drive, Brampton August 10, 2021 Ontario L6T 1C1 Submission Control No: 253784 _ _ _Pr_ _Taro-Docetaxel - Product Monograph _ _ _ _Page 2 of 57 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ..................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................27 DOSAGE AND ADMINISTRATION ..............................................................................28 OVERDOSAGE ................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ............................................................32 STORAGE AND STABILITY ..........................................................................................33 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................34 PART II: SCIENTIFIC INFORMATION ....................................................................35 PHARMACEUTICAL INFORMATION ..........................................................................35 CLINICAL TRIALS ............................................................. Read the complete document